nodes	percent_of_prediction	percent_of_DWPC	metapath
Crizotinib—MET—Gilles de la Tourette syndrome	0.828	1	CbGaD
Crizotinib—MUSK—nervous system—Gilles de la Tourette syndrome	0.00231	0.0153	CbGeAlD
Crizotinib—ROS1—brain—Gilles de la Tourette syndrome	0.00208	0.0138	CbGeAlD
Crizotinib—EPHA7—brain—Gilles de la Tourette syndrome	0.0019	0.0126	CbGeAlD
Crizotinib—ANKK1—nervous system—Gilles de la Tourette syndrome	0.00188	0.0125	CbGeAlD
Crizotinib—NTRK1—midbrain—Gilles de la Tourette syndrome	0.00174	0.0115	CbGeAlD
Crizotinib—LIMK1—midbrain—Gilles de la Tourette syndrome	0.00148	0.00977	CbGeAlD
Crizotinib—DSTYK—midbrain—Gilles de la Tourette syndrome	0.0014	0.0093	CbGeAlD
Crizotinib—MUSK—Extracellular matrix organization—COL27A1—Gilles de la Tourette syndrome	0.00137	0.0641	CbGpPWpGaD
Crizotinib—NEK9—nervous system—Gilles de la Tourette syndrome	0.00135	0.00894	CbGeAlD
Crizotinib—NEK9—central nervous system—Gilles de la Tourette syndrome	0.0013	0.0086	CbGeAlD
Crizotinib—PRKD1—nervous system—Gilles de la Tourette syndrome	0.00123	0.00815	CbGeAlD
Crizotinib—SIK2—nervous system—Gilles de la Tourette syndrome	0.00121	0.00804	CbGeAlD
Crizotinib—PRKD1—central nervous system—Gilles de la Tourette syndrome	0.00118	0.00784	CbGeAlD
Crizotinib—SIK2—central nervous system—Gilles de la Tourette syndrome	0.00117	0.00774	CbGeAlD
Crizotinib—MAPK7—nervous system—Gilles de la Tourette syndrome	0.00109	0.00724	CbGeAlD
Crizotinib—DCLK1—midbrain—Gilles de la Tourette syndrome	0.00109	0.00722	CbGeAlD
Crizotinib—EPHA8—nervous system—Gilles de la Tourette syndrome	0.00108	0.00716	CbGeAlD
Crizotinib—MAPK7—central nervous system—Gilles de la Tourette syndrome	0.00105	0.00697	CbGeAlD
Crizotinib—EPHA8—central nervous system—Gilles de la Tourette syndrome	0.00104	0.0069	CbGeAlD
Crizotinib—NEK9—brain—Gilles de la Tourette syndrome	0.00103	0.00683	CbGeAlD
Crizotinib—MET—nervous system—Gilles de la Tourette syndrome	0.00102	0.00677	CbGeAlD
Crizotinib—JAK2—Serotonin Receptor 2 and STAT3 Signaling—HTR2A—Gilles de la Tourette syndrome	0.00102	0.048	CbGpPWpGaD
Crizotinib—FER—midbrain—Gilles de la Tourette syndrome	0.00102	0.00674	CbGeAlD
Crizotinib—EPHA5—midbrain—Gilles de la Tourette syndrome	0.00102	0.00674	CbGeAlD
Crizotinib—ALK—midbrain—Gilles de la Tourette syndrome	0.00102	0.00674	CbGeAlD
Crizotinib—CDK7—nervous system—Gilles de la Tourette syndrome	0.000989	0.00655	CbGeAlD
Crizotinib—MET—central nervous system—Gilles de la Tourette syndrome	0.000984	0.00652	CbGeAlD
Crizotinib—MAP4K2—midbrain—Gilles de la Tourette syndrome	0.000964	0.00638	CbGeAlD
Crizotinib—CDK7—central nervous system—Gilles de la Tourette syndrome	0.000952	0.00631	CbGeAlD
Crizotinib—EPHA3—nervous system—Gilles de la Tourette syndrome	0.000945	0.00626	CbGeAlD
Crizotinib—ACVR1B—nervous system—Gilles de la Tourette syndrome	0.000945	0.00626	CbGeAlD
Crizotinib—PRKD1—brain—Gilles de la Tourette syndrome	0.00094	0.00623	CbGeAlD
Crizotinib—LIMK1—brain—Gilles de la Tourette syndrome	0.000927	0.00614	CbGeAlD
Crizotinib—SIK2—brain—Gilles de la Tourette syndrome	0.000927	0.00614	CbGeAlD
Crizotinib—TESK1—midbrain—Gilles de la Tourette syndrome	0.000919	0.00609	CbGeAlD
Crizotinib—EPHA3—central nervous system—Gilles de la Tourette syndrome	0.00091	0.00603	CbGeAlD
Crizotinib—ACVR1B—central nervous system—Gilles de la Tourette syndrome	0.00091	0.00603	CbGeAlD
Crizotinib—PRKD3—brain—Gilles de la Tourette syndrome	0.000904	0.00599	CbGeAlD
Crizotinib—JAK3—nervous system—Gilles de la Tourette syndrome	0.000901	0.00597	CbGeAlD
Crizotinib—EPHA6—nervous system—Gilles de la Tourette syndrome	0.000901	0.00597	CbGeAlD
Crizotinib—DCLK1—nervous system—Gilles de la Tourette syndrome	0.000896	0.00593	CbGeAlD
Crizotinib—STK4—nervous system—Gilles de la Tourette syndrome	0.000885	0.00586	CbGeAlD
Crizotinib—DSTYK—brain—Gilles de la Tourette syndrome	0.000882	0.00584	CbGeAlD
Crizotinib—JAK3—central nervous system—Gilles de la Tourette syndrome	0.000868	0.00575	CbGeAlD
Crizotinib—EPHA6—central nervous system—Gilles de la Tourette syndrome	0.000868	0.00575	CbGeAlD
Crizotinib—MAP3K12—midbrain—Gilles de la Tourette syndrome	0.000865	0.00573	CbGeAlD
Crizotinib—ACVR1—midbrain—Gilles de la Tourette syndrome	0.000865	0.00573	CbGeAlD
Crizotinib—DCLK1—central nervous system—Gilles de la Tourette syndrome	0.000862	0.00571	CbGeAlD
Crizotinib—LTK—brain—Gilles de la Tourette syndrome	0.000862	0.00571	CbGeAlD
Crizotinib—CASK—brain—Gilles de la Tourette syndrome	0.000862	0.00571	CbGeAlD
Crizotinib—STK4—central nervous system—Gilles de la Tourette syndrome	0.000852	0.00564	CbGeAlD
Crizotinib—STK35—midbrain—Gilles de la Tourette syndrome	0.000847	0.00561	CbGeAlD
Crizotinib—FER—nervous system—Gilles de la Tourette syndrome	0.000836	0.00554	CbGeAlD
Crizotinib—TYRO3—nervous system—Gilles de la Tourette syndrome	0.000836	0.00554	CbGeAlD
Crizotinib—EPHA5—nervous system—Gilles de la Tourette syndrome	0.000836	0.00554	CbGeAlD
Crizotinib—ALK—nervous system—Gilles de la Tourette syndrome	0.000836	0.00554	CbGeAlD
Crizotinib—MAPK7—brain—Gilles de la Tourette syndrome	0.000835	0.00553	CbGeAlD
Crizotinib—LYN—nervous system—Gilles de la Tourette syndrome	0.000832	0.00551	CbGeAlD
Crizotinib—EPHA8—brain—Gilles de la Tourette syndrome	0.000826	0.00547	CbGeAlD
Crizotinib—FES—brain—Gilles de la Tourette syndrome	0.000826	0.00547	CbGeAlD
Crizotinib—MAP3K19—nervous system—Gilles de la Tourette syndrome	0.000819	0.00543	CbGeAlD
Crizotinib—BMPR1B—nervous system—Gilles de la Tourette syndrome	0.000819	0.00543	CbGeAlD
Crizotinib—BMP2K—midbrain—Gilles de la Tourette syndrome	0.000816	0.0054	CbGeAlD
Crizotinib—ALK—central nervous system—Gilles de la Tourette syndrome	0.000805	0.00533	CbGeAlD
Crizotinib—FER—central nervous system—Gilles de la Tourette syndrome	0.000805	0.00533	CbGeAlD
Crizotinib—TYRO3—central nervous system—Gilles de la Tourette syndrome	0.000805	0.00533	CbGeAlD
Crizotinib—EPHA5—central nervous system—Gilles de la Tourette syndrome	0.000805	0.00533	CbGeAlD
Crizotinib—IGF1R—nervous system—Gilles de la Tourette syndrome	0.000803	0.00532	CbGeAlD
Crizotinib—TNK2—nervous system—Gilles de la Tourette syndrome	0.000803	0.00532	CbGeAlD
Crizotinib—LYN—central nervous system—Gilles de la Tourette syndrome	0.000801	0.00531	CbGeAlD
Crizotinib—BMPR1B—central nervous system—Gilles de la Tourette syndrome	0.000789	0.00523	CbGeAlD
Crizotinib—MAP3K19—central nervous system—Gilles de la Tourette syndrome	0.000789	0.00523	CbGeAlD
Crizotinib—TIE1—nervous system—Gilles de la Tourette syndrome	0.000782	0.00518	CbGeAlD
Crizotinib—MET—brain—Gilles de la Tourette syndrome	0.000781	0.00518	CbGeAlD
Crizotinib—RIPK2—midbrain—Gilles de la Tourette syndrome	0.000781	0.00518	CbGeAlD
Crizotinib—TNK2—central nervous system—Gilles de la Tourette syndrome	0.000774	0.00512	CbGeAlD
Crizotinib—IGF1R—central nervous system—Gilles de la Tourette syndrome	0.000774	0.00512	CbGeAlD
Crizotinib—AURKA—nervous system—Gilles de la Tourette syndrome	0.000762	0.00505	CbGeAlD
Crizotinib—CDK7—brain—Gilles de la Tourette syndrome	0.000756	0.00501	CbGeAlD
Crizotinib—TESK1—nervous system—Gilles de la Tourette syndrome	0.000755	0.005	CbGeAlD
Crizotinib—TIE1—central nervous system—Gilles de la Tourette syndrome	0.000753	0.00499	CbGeAlD
Crizotinib—TAOK2—brain—Gilles de la Tourette syndrome	0.00075	0.00497	CbGeAlD
Crizotinib—CASK—Extracellular matrix organization—COL27A1—Gilles de la Tourette syndrome	0.000748	0.0351	CbGpPWpGaD
Crizotinib—MERTK—nervous system—Gilles de la Tourette syndrome	0.000735	0.00487	CbGeAlD
Crizotinib—AURKA—central nervous system—Gilles de la Tourette syndrome	0.000733	0.00486	CbGeAlD
Crizotinib—TESK1—central nervous system—Gilles de la Tourette syndrome	0.000727	0.00482	CbGeAlD
Crizotinib—PTK2—midbrain—Gilles de la Tourette syndrome	0.000725	0.00481	CbGeAlD
Crizotinib—TBK1—midbrain—Gilles de la Tourette syndrome	0.000725	0.00481	CbGeAlD
Crizotinib—EPHA3—brain—Gilles de la Tourette syndrome	0.000722	0.00479	CbGeAlD
Crizotinib—ACVR1B—brain—Gilles de la Tourette syndrome	0.000722	0.00479	CbGeAlD
Crizotinib—TYK2—midbrain—Gilles de la Tourette syndrome	0.000721	0.00477	CbGeAlD
Crizotinib—LIMK2—nervous system—Gilles de la Tourette syndrome	0.000719	0.00476	CbGeAlD
Crizotinib—IRAK1—midbrain—Gilles de la Tourette syndrome	0.000711	0.00471	CbGeAlD
Crizotinib—MAP3K12—nervous system—Gilles de la Tourette syndrome	0.000711	0.00471	CbGeAlD
Crizotinib—ACVR1—nervous system—Gilles de la Tourette syndrome	0.000711	0.00471	CbGeAlD
Crizotinib—MERTK—central nervous system—Gilles de la Tourette syndrome	0.000708	0.00469	CbGeAlD
Crizotinib—RPS6KB1—midbrain—Gilles de la Tourette syndrome	0.000698	0.00462	CbGeAlD
Crizotinib—STK35—nervous system—Gilles de la Tourette syndrome	0.000697	0.00462	CbGeAlD
Crizotinib—LIMK2—central nervous system—Gilles de la Tourette syndrome	0.000692	0.00458	CbGeAlD
Crizotinib—AXL—midbrain—Gilles de la Tourette syndrome	0.000691	0.00458	CbGeAlD
Crizotinib—EPHA6—brain—Gilles de la Tourette syndrome	0.000689	0.00456	CbGeAlD
Crizotinib—JAK3—brain—Gilles de la Tourette syndrome	0.000689	0.00456	CbGeAlD
Crizotinib—DCLK1—brain—Gilles de la Tourette syndrome	0.000685	0.00454	CbGeAlD
Crizotinib—MAP3K12—central nervous system—Gilles de la Tourette syndrome	0.000685	0.00454	CbGeAlD
Crizotinib—ACVR1—central nervous system—Gilles de la Tourette syndrome	0.000685	0.00454	CbGeAlD
Crizotinib—PLK4—brain—Gilles de la Tourette syndrome	0.00068	0.00451	CbGeAlD
Crizotinib—STK4—brain—Gilles de la Tourette syndrome	0.000676	0.00448	CbGeAlD
Crizotinib—STK35—central nervous system—Gilles de la Tourette syndrome	0.000671	0.00444	CbGeAlD
Crizotinib—BMP2K—nervous system—Gilles de la Tourette syndrome	0.000671	0.00444	CbGeAlD
Crizotinib—SLK—midbrain—Gilles de la Tourette syndrome	0.000665	0.00441	CbGeAlD
Crizotinib—EPHB4—midbrain—Gilles de la Tourette syndrome	0.00066	0.00437	CbGeAlD
Crizotinib—PTK2B—nervous system—Gilles de la Tourette syndrome	0.000648	0.00429	CbGeAlD
Crizotinib—BMP2K—central nervous system—Gilles de la Tourette syndrome	0.000646	0.00428	CbGeAlD
Crizotinib—TYRO3—brain—Gilles de la Tourette syndrome	0.000639	0.00423	CbGeAlD
Crizotinib—FER—brain—Gilles de la Tourette syndrome	0.000639	0.00423	CbGeAlD
Crizotinib—EPHA5—brain—Gilles de la Tourette syndrome	0.000639	0.00423	CbGeAlD
Crizotinib—ALK—brain—Gilles de la Tourette syndrome	0.000639	0.00423	CbGeAlD
Crizotinib—LYN—brain—Gilles de la Tourette syndrome	0.000636	0.00421	CbGeAlD
Crizotinib—TNK1—brain—Gilles de la Tourette syndrome	0.000633	0.00419	CbGeAlD
Crizotinib—MAP4K5—midbrain—Gilles de la Tourette syndrome	0.000632	0.00419	CbGeAlD
Crizotinib—TEK—midbrain—Gilles de la Tourette syndrome	0.000632	0.00419	CbGeAlD
Crizotinib—MAP3K3—midbrain—Gilles de la Tourette syndrome	0.000632	0.00419	CbGeAlD
Crizotinib—MAP4K1—brain—Gilles de la Tourette syndrome	0.000626	0.00415	CbGeAlD
Crizotinib—BMPR1B—brain—Gilles de la Tourette syndrome	0.000626	0.00415	CbGeAlD
Crizotinib—MAP3K19—brain—Gilles de la Tourette syndrome	0.000626	0.00415	CbGeAlD
Crizotinib—PTK2B—central nervous system—Gilles de la Tourette syndrome	0.000624	0.00413	CbGeAlD
Crizotinib—EPHA4—nervous system—Gilles de la Tourette syndrome	0.000621	0.00411	CbGeAlD
Crizotinib—TNK2—brain—Gilles de la Tourette syndrome	0.000614	0.00407	CbGeAlD
Crizotinib—IGF1R—brain—Gilles de la Tourette syndrome	0.000614	0.00407	CbGeAlD
Crizotinib—MAP3K2—nervous system—Gilles de la Tourette syndrome	0.000609	0.00403	CbGeAlD
Crizotinib—MAP4K2—brain—Gilles de la Tourette syndrome	0.000606	0.00401	CbGeAlD
Crizotinib—EPHB6—midbrain—Gilles de la Tourette syndrome	0.000604	0.004	CbGeAlD
Crizotinib—EPHA4—central nervous system—Gilles de la Tourette syndrome	0.000598	0.00396	CbGeAlD
Crizotinib—STK3—brain—Gilles de la Tourette syndrome	0.000597	0.00396	CbGeAlD
Crizotinib—TIE1—brain—Gilles de la Tourette syndrome	0.000597	0.00396	CbGeAlD
Crizotinib—TBK1—nervous system—Gilles de la Tourette syndrome	0.000596	0.00395	CbGeAlD
Crizotinib—PTK2—nervous system—Gilles de la Tourette syndrome	0.000596	0.00395	CbGeAlD
Crizotinib—TYK2—nervous system—Gilles de la Tourette syndrome	0.000592	0.00392	CbGeAlD
Crizotinib—MAP3K2—central nervous system—Gilles de la Tourette syndrome	0.000586	0.00388	CbGeAlD
Crizotinib—YES1—midbrain—Gilles de la Tourette syndrome	0.000584	0.00387	CbGeAlD
Crizotinib—AURKA—brain—Gilles de la Tourette syndrome	0.000582	0.00386	CbGeAlD
Crizotinib—TESK1—brain—Gilles de la Tourette syndrome	0.000577	0.00383	CbGeAlD
Crizotinib—TAOK3—midbrain—Gilles de la Tourette syndrome	0.000576	0.00382	CbGeAlD
Crizotinib—PTK2—central nervous system—Gilles de la Tourette syndrome	0.000574	0.0038	CbGeAlD
Crizotinib—TBK1—central nervous system—Gilles de la Tourette syndrome	0.000574	0.0038	CbGeAlD
Crizotinib—RPS6KB1—nervous system—Gilles de la Tourette syndrome	0.000574	0.0038	CbGeAlD
Crizotinib—CASK—Syndecan-1-mediated signaling events—MET—Gilles de la Tourette syndrome	0.00057	0.0268	CbGpPWpGaD
Crizotinib—TYK2—central nervous system—Gilles de la Tourette syndrome	0.00057	0.00378	CbGeAlD
Crizotinib—FGR—nervous system—Gilles de la Tourette syndrome	0.00057	0.00378	CbGeAlD
Crizotinib—LIMK2—Sema4D in semaphorin signaling—MET—Gilles de la Tourette syndrome	0.000568	0.0267	CbGpPWpGaD
Crizotinib—AXL—nervous system—Gilles de la Tourette syndrome	0.000568	0.00376	CbGeAlD
Crizotinib—MERTK—brain—Gilles de la Tourette syndrome	0.000562	0.00372	CbGeAlD
Crizotinib—LIMK1—Sema4D in semaphorin signaling—MET—Gilles de la Tourette syndrome	0.000556	0.0261	CbGpPWpGaD
Crizotinib—RPS6KB1—central nervous system—Gilles de la Tourette syndrome	0.000552	0.00366	CbGeAlD
Crizotinib—LIMK2—brain—Gilles de la Tourette syndrome	0.000549	0.00364	CbGeAlD
Crizotinib—FGR—central nervous system—Gilles de la Tourette syndrome	0.000549	0.00364	CbGeAlD
Crizotinib—NUAK2—brain—Gilles de la Tourette syndrome	0.000547	0.00363	CbGeAlD
Crizotinib—AXL—central nervous system—Gilles de la Tourette syndrome	0.000547	0.00362	CbGeAlD
Crizotinib—MAP3K12—brain—Gilles de la Tourette syndrome	0.000544	0.0036	CbGeAlD
Crizotinib—ACVR1—brain—Gilles de la Tourette syndrome	0.000544	0.0036	CbGeAlD
Crizotinib—JAK2—nervous system—Gilles de la Tourette syndrome	0.000539	0.00357	CbGeAlD
Crizotinib—STK35—brain—Gilles de la Tourette syndrome	0.000532	0.00353	CbGeAlD
Crizotinib—EPHA2—nervous system—Gilles de la Tourette syndrome	0.000532	0.00353	CbGeAlD
Crizotinib—PTK2B—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.000527	0.0247	CbGpPWpGaD
Crizotinib—TEK—nervous system—Gilles de la Tourette syndrome	0.000519	0.00344	CbGeAlD
Crizotinib—MAP4K5—nervous system—Gilles de la Tourette syndrome	0.000519	0.00344	CbGeAlD
Crizotinib—MAP3K3—nervous system—Gilles de la Tourette syndrome	0.000519	0.00344	CbGeAlD
Crizotinib—ABL2—brain—Gilles de la Tourette syndrome	0.000519	0.00344	CbGeAlD
Crizotinib—JAK2—central nervous system—Gilles de la Tourette syndrome	0.000519	0.00344	CbGeAlD
Crizotinib—BLK—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.000514	0.0241	CbGpPWpGaD
Crizotinib—EPHA2—central nervous system—Gilles de la Tourette syndrome	0.000513	0.0034	CbGeAlD
Crizotinib—BMP2K—brain—Gilles de la Tourette syndrome	0.000513	0.0034	CbGeAlD
Crizotinib—FGR—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.000512	0.0241	CbGpPWpGaD
Crizotinib—CSF1R—midbrain—Gilles de la Tourette syndrome	0.000504	0.00334	CbGeAlD
Crizotinib—TEK—central nervous system—Gilles de la Tourette syndrome	0.0005	0.00331	CbGeAlD
Crizotinib—MAP4K5—central nervous system—Gilles de la Tourette syndrome	0.0005	0.00331	CbGeAlD
Crizotinib—MAP3K3—central nervous system—Gilles de la Tourette syndrome	0.0005	0.00331	CbGeAlD
Crizotinib—EPHB6—nervous system—Gilles de la Tourette syndrome	0.000496	0.00329	CbGeAlD
Crizotinib—PTK2B—brain—Gilles de la Tourette syndrome	0.000495	0.00328	CbGeAlD
Crizotinib—RIPK2—brain—Gilles de la Tourette syndrome	0.000491	0.00325	CbGeAlD
Crizotinib—YES1—nervous system—Gilles de la Tourette syndrome	0.00048	0.00318	CbGeAlD
Crizotinib—EPHB6—central nervous system—Gilles de la Tourette syndrome	0.000478	0.00317	CbGeAlD
Crizotinib—STK10—nervous system—Gilles de la Tourette syndrome	0.000475	0.00315	CbGeAlD
Crizotinib—EPHA4—brain—Gilles de la Tourette syndrome	0.000475	0.00314	CbGeAlD
Crizotinib—TAOK3—nervous system—Gilles de la Tourette syndrome	0.000474	0.00314	CbGeAlD
Crizotinib—MAP3K2—brain—Gilles de la Tourette syndrome	0.000465	0.00308	CbGeAlD
Crizotinib—YES1—central nervous system—Gilles de la Tourette syndrome	0.000462	0.00306	CbGeAlD
Crizotinib—SRC—nervous system—Gilles de la Tourette syndrome	0.000461	0.00306	CbGeAlD
Crizotinib—STK10—central nervous system—Gilles de la Tourette syndrome	0.000458	0.00303	CbGeAlD
Crizotinib—TAOK3—central nervous system—Gilles de la Tourette syndrome	0.000456	0.00302	CbGeAlD
Crizotinib—TBK1—brain—Gilles de la Tourette syndrome	0.000456	0.00302	CbGeAlD
Crizotinib—PTK2—brain—Gilles de la Tourette syndrome	0.000456	0.00302	CbGeAlD
Crizotinib—TYK2—brain—Gilles de la Tourette syndrome	0.000453	0.003	CbGeAlD
Crizotinib—IRAK1—brain—Gilles de la Tourette syndrome	0.000447	0.00296	CbGeAlD
Crizotinib—SRC—central nervous system—Gilles de la Tourette syndrome	0.000444	0.00294	CbGeAlD
Crizotinib—RPS6KB1—brain—Gilles de la Tourette syndrome	0.000439	0.00291	CbGeAlD
Crizotinib—FGR—brain—Gilles de la Tourette syndrome	0.000436	0.00289	CbGeAlD
Crizotinib—AXL—brain—Gilles de la Tourette syndrome	0.000434	0.00288	CbGeAlD
Crizotinib—MAP4K1—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.000421	0.0198	CbGpPWpGaD
Crizotinib—SLK—brain—Gilles de la Tourette syndrome	0.000418	0.00277	CbGeAlD
Crizotinib—EPHB4—brain—Gilles de la Tourette syndrome	0.000415	0.00275	CbGeAlD
Crizotinib—CSF1R—nervous system—Gilles de la Tourette syndrome	0.000414	0.00274	CbGeAlD
Crizotinib—YES1—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.000414	0.0194	CbGpPWpGaD
Crizotinib—JAK2—brain—Gilles de la Tourette syndrome	0.000412	0.00273	CbGeAlD
Crizotinib—EPHA2—brain—Gilles de la Tourette syndrome	0.000407	0.0027	CbGeAlD
Crizotinib—IGF1R—Stabilization and expansion of the E-cadherin adherens junction—MET—Gilles de la Tourette syndrome	0.000399	0.0187	CbGpPWpGaD
Crizotinib—CSF1R—central nervous system—Gilles de la Tourette syndrome	0.000399	0.00264	CbGeAlD
Crizotinib—ABL1—midbrain—Gilles de la Tourette syndrome	0.000398	0.00264	CbGeAlD
Crizotinib—MAP3K3—brain—Gilles de la Tourette syndrome	0.000397	0.00263	CbGeAlD
Crizotinib—TEK—brain—Gilles de la Tourette syndrome	0.000397	0.00263	CbGeAlD
Crizotinib—MAP4K5—brain—Gilles de la Tourette syndrome	0.000397	0.00263	CbGeAlD
Crizotinib—EPHB6—brain—Gilles de la Tourette syndrome	0.000379	0.00251	CbGeAlD
Crizotinib—EPHA2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.000376	0.0177	CbGpPWpGaD
Crizotinib—CSF1R—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.00037	0.0174	CbGpPWpGaD
Crizotinib—YES1—brain—Gilles de la Tourette syndrome	0.000367	0.00243	CbGeAlD
Crizotinib—STK10—brain—Gilles de la Tourette syndrome	0.000363	0.00241	CbGeAlD
Crizotinib—TAOK3—brain—Gilles de la Tourette syndrome	0.000362	0.0024	CbGeAlD
Crizotinib—IGF1R—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000359	0.0168	CbGpPWpGaD
Crizotinib—SRC—brain—Gilles de la Tourette syndrome	0.000353	0.00234	CbGeAlD
Crizotinib—ABL1—nervous system—Gilles de la Tourette syndrome	0.000327	0.00217	CbGeAlD
Crizotinib—EPHA2—Stabilization and expansion of the E-cadherin adherens junction—MET—Gilles de la Tourette syndrome	0.000325	0.0153	CbGpPWpGaD
Crizotinib—TNK1—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000322	0.0151	CbGpPWpGaD
Crizotinib—CSF1R—brain—Gilles de la Tourette syndrome	0.000317	0.0021	CbGeAlD
Crizotinib—ABL1—central nervous system—Gilles de la Tourette syndrome	0.000315	0.00209	CbGeAlD
Crizotinib—LYN—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.000308	0.0145	CbGpPWpGaD
Crizotinib—FES—Semaphorin interactions—MET—Gilles de la Tourette syndrome	0.000304	0.0143	CbGpPWpGaD
Crizotinib—PTK2B—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.0003	0.0141	CbGpPWpGaD
Crizotinib—JAK3—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.0003	0.0141	CbGpPWpGaD
Crizotinib—LIMK2—Semaphorin interactions—MET—Gilles de la Tourette syndrome	0.000275	0.0129	CbGpPWpGaD
Crizotinib—LIMK1—Semaphorin interactions—MET—Gilles de la Tourette syndrome	0.000269	0.0126	CbGpPWpGaD
Crizotinib—LCK—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.000253	0.0119	CbGpPWpGaD
Crizotinib—EPHA3—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000252	0.0118	CbGpPWpGaD
Crizotinib—ABL1—brain—Gilles de la Tourette syndrome	0.00025	0.00166	CbGeAlD
Crizotinib—PTK2—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.000239	0.0112	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	0.000234	0.011	CbGpPWpGaD
Crizotinib—SRC—Alpha-synuclein signaling—SLC6A3—Gilles de la Tourette syndrome	0.000224	0.0105	CbGpPWpGaD
Crizotinib—RPS6KB1—a6b1 and a6b4 Integrin signaling—MET—Gilles de la Tourette syndrome	0.000223	0.0104	CbGpPWpGaD
Crizotinib—PTK2B—FGF signaling pathway—MET—Gilles de la Tourette syndrome	0.000207	0.00973	CbGpPWpGaD
Crizotinib—EPHA2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000196	0.00919	CbGpPWpGaD
Crizotinib—TXK—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000169	0.00795	CbGpPWpGaD
Crizotinib—TNK2—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000165	0.00774	CbGpPWpGaD
Crizotinib—LIMK2—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.00016	0.00749	CbGpPWpGaD
Crizotinib—PRKD1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000151	0.00709	CbGpPWpGaD
Crizotinib—EPHA7—Axon guidance—MET—Gilles de la Tourette syndrome	0.00015	0.00703	CbGpPWpGaD
Crizotinib—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.000144	0.000953	CbGeAlD
Crizotinib—MAP4K1—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	0.000142	0.00668	CbGpPWpGaD
Crizotinib—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.000139	0.000918	CbGeAlD
Crizotinib—ABL1—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	0.000133	0.00623	CbGpPWpGaD
Crizotinib—SRC—Signaling of Hepatocyte Growth Factor Receptor—MET—Gilles de la Tourette syndrome	0.000128	0.00598	CbGpPWpGaD
Crizotinib—SRC—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.000125	0.00585	CbGpPWpGaD
Crizotinib—EPHA2—Direct p53 effectors—MET—Gilles de la Tourette syndrome	0.000124	0.00583	CbGpPWpGaD
Crizotinib—ABCB1—midbrain—Gilles de la Tourette syndrome	0.000124	0.000821	CbGeAlD
Crizotinib—NTRK1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000123	0.00576	CbGpPWpGaD
Crizotinib—PTK2—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	0.000121	0.00566	CbGpPWpGaD
Crizotinib—IGF1R—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000119	0.0056	CbGpPWpGaD
Crizotinib—NTRK1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000119	0.00559	CbGpPWpGaD
Crizotinib—MAPK7—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000119	0.00557	CbGpPWpGaD
Crizotinib—MAPK7—Focal Adhesion—MET—Gilles de la Tourette syndrome	0.000117	0.00548	CbGpPWpGaD
Crizotinib—SRC—Signaling events mediated by TCPTP—MET—Gilles de la Tourette syndrome	0.000112	0.00525	CbGpPWpGaD
Crizotinib—NTRK1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.000111	0.00521	CbGpPWpGaD
Crizotinib—EPHA7—Developmental Biology—MET—Gilles de la Tourette syndrome	0.000107	0.00502	CbGpPWpGaD
Crizotinib—ABL1—Regulation of retinoblastoma protein—MET—Gilles de la Tourette syndrome	0.000103	0.00483	CbGpPWpGaD
Crizotinib—ABCB1—nervous system—Gilles de la Tourette syndrome	0.000102	0.000675	CbGeAlD
Crizotinib—ABCB1—central nervous system—Gilles de la Tourette syndrome	9.8e-05	0.00065	CbGeAlD
Crizotinib—SRC—Posttranslational regulation of adherens junction stability and dissassembly—MET—Gilles de la Tourette syndrome	9.68e-05	0.00454	CbGpPWpGaD
Crizotinib—SRC—FGF signaling pathway—MET—Gilles de la Tourette syndrome	8.81e-05	0.00413	CbGpPWpGaD
Crizotinib—FES—Axon guidance—MET—Gilles de la Tourette syndrome	8.61e-05	0.00404	CbGpPWpGaD
Crizotinib—EPHA5—Axon guidance—MET—Gilles de la Tourette syndrome	8.16e-05	0.00383	CbGpPWpGaD
Crizotinib—EPHA3—Axon guidance—MET—Gilles de la Tourette syndrome	8.16e-05	0.00383	CbGpPWpGaD
Crizotinib—ABL2—Axon guidance—MET—Gilles de la Tourette syndrome	8.16e-05	0.00383	CbGpPWpGaD
Crizotinib—ACVR1B—Developmental Biology—MET—Gilles de la Tourette syndrome	8.1e-05	0.0038	CbGpPWpGaD
Crizotinib—PTK2—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	8.07e-05	0.00379	CbGpPWpGaD
Crizotinib—EPHA8—Axon guidance—MET—Gilles de la Tourette syndrome	7.87e-05	0.00369	CbGpPWpGaD
Crizotinib—ABCB1—brain—Gilles de la Tourette syndrome	7.78e-05	0.000516	CbGeAlD
Crizotinib—LIMK2—Axon guidance—MET—Gilles de la Tourette syndrome	7.78e-05	0.00365	CbGpPWpGaD
Crizotinib—EPHB4—Axon guidance—MET—Gilles de la Tourette syndrome	7.78e-05	0.00365	CbGpPWpGaD
Crizotinib—EPHA4—Axon guidance—MET—Gilles de la Tourette syndrome	7.78e-05	0.00365	CbGpPWpGaD
Crizotinib—LIMK1—Axon guidance—MET—Gilles de la Tourette syndrome	7.62e-05	0.00358	CbGpPWpGaD
Crizotinib—BLK—Focal Adhesion—MET—Gilles de la Tourette syndrome	7.4e-05	0.00347	CbGpPWpGaD
Crizotinib—FGR—Focal Adhesion—MET—Gilles de la Tourette syndrome	7.37e-05	0.00346	CbGpPWpGaD
Crizotinib—EPHB6—Axon guidance—MET—Gilles de la Tourette syndrome	7.32e-05	0.00344	CbGpPWpGaD
Crizotinib—EPHA6—Axon guidance—MET—Gilles de la Tourette syndrome	6.88e-05	0.00323	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	6.7e-05	0.00314	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	6.5e-05	0.00305	CbGpPWpGaD
Crizotinib—SRC—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—MET—Gilles de la Tourette syndrome	6.43e-05	0.00302	CbGpPWpGaD
Crizotinib—EPHA2—Axon guidance—MET—Gilles de la Tourette syndrome	6.35e-05	0.00298	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways in Glioblastoma—MET—Gilles de la Tourette syndrome	6.3e-05	0.00296	CbGpPWpGaD
Crizotinib—FES—Developmental Biology—MET—Gilles de la Tourette syndrome	6.14e-05	0.00288	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	6.06e-05	0.00284	CbGpPWpGaD
Crizotinib—PTK2—Focal Adhesion—MET—Gilles de la Tourette syndrome	6.03e-05	0.00283	CbGpPWpGaD
Crizotinib—EPHA5—Developmental Biology—MET—Gilles de la Tourette syndrome	5.82e-05	0.00273	CbGpPWpGaD
Crizotinib—ABL2—Developmental Biology—MET—Gilles de la Tourette syndrome	5.82e-05	0.00273	CbGpPWpGaD
Crizotinib—EPHA3—Developmental Biology—MET—Gilles de la Tourette syndrome	5.82e-05	0.00273	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.7e-05	0.00267	CbGpPWpGaD
Crizotinib—EPHA8—Developmental Biology—MET—Gilles de la Tourette syndrome	5.62e-05	0.00264	CbGpPWpGaD
Crizotinib—TYK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	5.57e-05	0.00261	CbGpPWpGaD
Crizotinib—EPHB4—Developmental Biology—MET—Gilles de la Tourette syndrome	5.55e-05	0.00261	CbGpPWpGaD
Crizotinib—LIMK2—Developmental Biology—MET—Gilles de la Tourette syndrome	5.55e-05	0.00261	CbGpPWpGaD
Crizotinib—EPHA4—Developmental Biology—MET—Gilles de la Tourette syndrome	5.55e-05	0.00261	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.53e-05	0.0026	CbGpPWpGaD
Crizotinib—LIMK1—Developmental Biology—MET—Gilles de la Tourette syndrome	5.44e-05	0.00255	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	5.42e-05	0.00254	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.26e-05	0.00247	CbGpPWpGaD
Crizotinib—EPHB6—Developmental Biology—MET—Gilles de la Tourette syndrome	5.22e-05	0.00245	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	5.15e-05	0.00242	CbGpPWpGaD
Crizotinib—EPHA6—Developmental Biology—MET—Gilles de la Tourette syndrome	4.91e-05	0.0023	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	4.9e-05	0.0023	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.77e-05	0.00224	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.77e-05	0.00224	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.63e-05	0.00218	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.63e-05	0.00218	CbGpPWpGaD
Crizotinib—EPHA2—Developmental Biology—MET—Gilles de la Tourette syndrome	4.53e-05	0.00213	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.53e-05	0.00212	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	4.41e-05	0.00207	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.39e-05	0.00206	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.32e-05	0.00203	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.32e-05	0.00203	CbGpPWpGaD
Crizotinib—SRC—TGF-beta Signaling Pathway—MET—Gilles de la Tourette syndrome	4.31e-05	0.00202	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	4.28e-05	0.00201	CbGpPWpGaD
Crizotinib—STK4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	4.24e-05	0.00199	CbGpPWpGaD
Crizotinib—JAK2—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	4.22e-05	0.00198	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.14e-05	0.00194	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.09e-05	0.00192	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.02e-05	0.00189	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	4e-05	0.00188	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	3.99e-05	0.00187	CbGpPWpGaD
Crizotinib—PTK2—Axon guidance—MET—Gilles de la Tourette syndrome	3.94e-05	0.00185	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	3.89e-05	0.00182	CbGpPWpGaD
Crizotinib—YES1—Axon guidance—MET—Gilles de la Tourette syndrome	3.88e-05	0.00182	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.74e-05	0.00176	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	3.62e-05	0.0017	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.62e-05	0.0017	CbGpPWpGaD
Crizotinib—STK3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.61e-05	0.00169	CbGpPWpGaD
Crizotinib—TYK2—Axon guidance—MET—Gilles de la Tourette syndrome	3.57e-05	0.00168	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.51e-05	0.00165	CbGpPWpGaD
Crizotinib—MAPK7—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.43e-05	0.00161	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.27e-05	0.00154	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.27e-05	0.00154	CbGpPWpGaD
Crizotinib—SRC—Focal Adhesion—MET—Gilles de la Tourette syndrome	3.22e-05	0.00151	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.2e-05	0.0015	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.18e-05	0.00149	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.11e-05	0.00146	CbGpPWpGaD
Crizotinib—FER—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.02e-05	0.00142	CbGpPWpGaD
Crizotinib—ACVR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.02e-05	0.00142	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.96e-05	0.00139	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.9e-05	0.00136	CbGpPWpGaD
Crizotinib—LYN—Axon guidance—MET—Gilles de la Tourette syndrome	2.89e-05	0.00136	CbGpPWpGaD
Crizotinib—ABL1—Axon guidance—MET—Gilles de la Tourette syndrome	2.88e-05	0.00135	CbGpPWpGaD
Crizotinib—AXL—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.87e-05	0.00135	CbGpPWpGaD
Crizotinib—PTK2—Developmental Biology—MET—Gilles de la Tourette syndrome	2.81e-05	0.00132	CbGpPWpGaD
Crizotinib—JAK3—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	2.79e-05	0.00131	CbGpPWpGaD
Crizotinib—YES1—Developmental Biology—MET—Gilles de la Tourette syndrome	2.77e-05	0.0013	CbGpPWpGaD
Crizotinib—JAK2—Axon guidance—MET—Gilles de la Tourette syndrome	2.71e-05	0.00127	CbGpPWpGaD
Crizotinib—BMPR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.62e-05	0.00123	CbGpPWpGaD
Crizotinib—TYK2—Developmental Biology—MET—Gilles de la Tourette syndrome	2.55e-05	0.0012	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	2.54e-05	0.00119	CbGpPWpGaD
Crizotinib—JAK3—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	2.54e-05	0.00119	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	2.47e-05	0.00116	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.37e-05	0.00111	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	2.3e-05	0.00108	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.3e-05	0.00108	CbGpPWpGaD
Crizotinib—FES—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.29e-05	0.00108	CbGpPWpGaD
Crizotinib—CYP3A5—Metabolism—HDC—Gilles de la Tourette syndrome	2.19e-05	0.00103	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	2.14e-05	0.001	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	2.12e-05	0.000996	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.11e-05	0.00099	CbGpPWpGaD
Crizotinib—SRC—Axon guidance—MET—Gilles de la Tourette syndrome	2.1e-05	0.000986	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	2.08e-05	0.000975	CbGpPWpGaD
Crizotinib—IGF1R—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.07e-05	0.000973	CbGpPWpGaD
Crizotinib—LYN—Developmental Biology—MET—Gilles de la Tourette syndrome	2.07e-05	0.000969	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	2.06e-05	0.000967	CbGpPWpGaD
Crizotinib—ABL1—Developmental Biology—MET—Gilles de la Tourette syndrome	2.06e-05	0.000965	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.05e-05	0.000961	CbGpPWpGaD
Crizotinib—MAPK7—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.03e-05	0.000952	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	2.02e-05	0.000947	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.99e-05	0.000933	CbGpPWpGaD
Crizotinib—JAK2—Developmental Biology—MET—Gilles de la Tourette syndrome	1.93e-05	0.000907	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.93e-05	0.000906	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.93e-05	0.000905	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	1.93e-05	0.000905	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	1.92e-05	0.000901	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.91e-05	0.000895	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.88e-05	0.000882	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.87e-05	0.000879	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	1.87e-05	0.000878	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.8e-05	0.000844	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.74e-05	0.000819	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	1.74e-05	0.000818	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.65e-05	0.000777	CbGpPWpGaD
Crizotinib—ABCB1—Metabolism—HDC—Gilles de la Tourette syndrome	1.65e-05	0.000775	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.63e-05	0.000766	CbGpPWpGaD
Crizotinib—TYK2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	1.61e-05	0.000756	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.61e-05	0.000754	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.58e-05	0.000744	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.55e-05	0.000726	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.5e-05	0.000705	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.5e-05	0.000705	CbGpPWpGaD
Crizotinib—SRC—Developmental Biology—MET—Gilles de la Tourette syndrome	1.5e-05	0.000703	CbGpPWpGaD
Crizotinib—JAK3—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.5e-05	0.000703	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.5e-05	0.000702	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.48e-05	0.000693	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.46e-05	0.000685	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.4e-05	0.000657	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.36e-05	0.000638	CbGpPWpGaD
Crizotinib—JAK2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	1.34e-05	0.000631	CbGpPWpGaD
Crizotinib—RIPK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.34e-05	0.000627	CbGpPWpGaD
Crizotinib—PTK2B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.32e-05	0.000618	CbGpPWpGaD
Crizotinib—NTRK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.26e-05	0.000591	CbGpPWpGaD
Crizotinib—ABCB1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	1.23e-05	0.000576	CbGpPWpGaD
Crizotinib—RPS6KB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.22e-05	0.000573	CbGpPWpGaD
Crizotinib—JAK2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	1.22e-05	0.000573	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.22e-05	0.000571	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.18e-05	0.000554	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	1.14e-05	0.000534	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	1.11e-05	0.000519	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.1e-05	0.000516	CbGpPWpGaD
Crizotinib—PTK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.05e-05	0.000492	CbGpPWpGaD
Crizotinib—YES1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	1.03e-05	0.000485	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	1.03e-05	0.000483	CbGpPWpGaD
Crizotinib—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	1.02e-05	0.000478	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	9.97e-06	0.000468	CbGpPWpGaD
Crizotinib—IRAK1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.8e-06	0.00046	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	9.68e-06	0.000454	CbGpPWpGaD
Crizotinib—TYK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	9.52e-06	0.000447	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	9.02e-06	0.000423	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	8.83e-06	0.000414	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	8.57e-06	0.000402	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	7.98e-06	0.000375	CbGpPWpGaD
Crizotinib—LYN—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.71e-06	0.000362	CbGpPWpGaD
Crizotinib—JAK2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	7.21e-06	0.000339	CbGpPWpGaD
Crizotinib—LCK—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	6.32e-06	0.000296	CbGpPWpGaD
Crizotinib—SRC—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	5.59e-06	0.000262	CbGpPWpGaD
